New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2)

ACS Chemical Biology

Volumn 8, Issue 9, 2013, Pages 1947-1954

  Hu, Gang ^a   Henke, Adam ^a   Karpowicz, Richard J ^a   Sonders, Mark S ^a   Farrimond, Frances ^b   Edwards, Robert ^b   Sulzer, David ^a   Sames, Dalibor ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLUORESCENT DYE; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SYNAPSE VESICLE;

DRUG EVALUATION, PRECLINICAL; FLUORESCENT DYES; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSCOPY, FLUORESCENCE; SENSITIVITY AND SPECIFICITY; SMALL MOLECULE LIBRARIES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84884624929     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400259n     Document Type: Article

References (47)

1. Bamford, N. S., Zhang, H., Schmitz, Y., Wu, N.-P., Cepeda, C., Levine, M. S., Schmauss, C., Zakharenko, S. S., Zablow, L., and Sulzer, D. (2004) Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals Neuron 42, 653-663
2. Ellender, T. J., Huerta-Ocampo, I., Deisseroth, K., Capogna, M., and Bolam, J. P. (2011) Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine J. Neurosci. 31, 15340-15351
3. Mathur, B. N., Capik, N. A., Alvarez, V. A., and Lovinger, D. M. (2011) Serotonin induces long-term depression at corticostriatal synapses J. Neurosci. 31, 7402-7411
4. Verhoeff, N. P. (1999) Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders Psychopharmacology (Berlin, Ger.) 147, 217-249
5. Wimalasena, K. (2011) Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry Med. Res. Rev. 31, 483-519
6. Liu, Y., Peter, D., Roghani, A., Schuldiner, S., Prive, G. G., Eisenberg, D., Brecha, N., and Edwards, R. H. (1992) A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter Cell 70, 539-551
7. Liu, Y., Roghani, A., and Edwards, R. H. (1992) Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium Proc. Natl. Acad. Sci. U.S.A. 89, 9074-9078
8. Raffo, A., Hancock, K., Polito, T., Xie, Y., Andan, G., Witkowski, P., Hardy, M., Barba, P., Ferrara, C., Maffei, A., Freeby, M., Goland, R., Leibel, R. L., Sweet, I. R., and Harris, P. E. (2008) Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine J. Endocrinol. 198, 41-49
9. Peter, D., Liu, Y., Sternini, C., de Giorgio, R., Brecha, N., and Edwards, R. H. (1995) Differential expression of two vesicular monoamine transporters J. Neurosci. 15, 6179-6188
10. Peter, D., Jimenez, J., Liu, Y., Kim, J., and Edwards, R. H. (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors J. Biol. Chem. 269, 7231-7237
11. Erickson, J. D., Schafer, M. K., Bonner, T. I., Eiden, L. E., and Weihe, E. (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter Proc. Natl. Acad. Sci. U.S.A. 93, 5166-5171
12. Carlsson, A. (1966) Modification of sympathetic fuction Pharmacol. Rev. 18, 541-549
13. Zheng, G., Dwoskin, L. P., and Crooks, P. A. (2006) Vesicular monoamine transporter 2: Role as a novel target for drug development AAPS J. 8, E682-E692
14. Group, H. S. (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology 66, 366-372
15. Kenney, C. and Jankovic, J. (2006) Tetrabenazine in the treatment of hyperkinetic movement disorders Expert Rev. Neurother. 6, 7-17
16. Nickell, J. R., Krishnamurthy, S., Norrholm, S., Deaciuc, G., Siripurapu, K. B., Zheng, G., Crooks, P. A., and Dwoskin, L. P. (2010) Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2 J. Pharmacol. Exp. Ther. 332, 612-621
17. Horton, D. B., Siripurapu, K. B., Zheng, G., Crooks, P. A., and Dwoskin, L. P. (2011) Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release J. Pharmacol. Exp. Ther. 339, 286-297
18. Zhu, L., Liu, J., and Kung, H. F. (2009) Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2 Bioorg. Med. Chem. Lett. 19, 5026-5028
19. Zubieta, J.-K., Taylor, S. F., Huguelet, P., Koeppe, R. A., Kilbourn, M. R., and Frey, K. A. (2001) Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects Biol. Psychiatry 49, 110-116
20. Kilbourn, M. R. (1997) In vivo radiotracers for vesicular neurotransmitter transporters Nucl. Med. Biol. 24, 615-619
21. Koeppe, R. A., Gilman, S., Joshi, A., Liu, S., Little, R., Junck, L., Heumann, M., Frey, K. A., and Albin, R. L. (2005) 11C-DTBZ and 18F-FDG PET measures in differentiating dementias J. Nucl. Med. 46, 936-944
22. Souza, F., Simpson, N., Raffo, A., Saxena, C., Maffei, A., Hardy, M., Kilbourn, M., Goland, R., Leibel, R., Mann, J. J., Van Heertum, R., and Harris, P. E. (2006) Longitudinal noninvasive PET-based β cell mass estimates in a spontaneous diabetes rat model J. Clin. Invest. 116, 1506-1513
23. Simpson, N. R., Souza, F., Witkowski, P., Maffei, A., Raffo, A., Herron, A., Kilbourn, M., Jurewicz, A., Herold, K., Liu, E., Hardy, M. A., Van Heertum, R., and Harris, P. E. (2006) Visualizing pancreatic β-cell mass with [11C]DTBZ Nucl. Med. Biol. 33, 855-864
24. Guillot, T. S., Richardson, J. R., Wang, M. Z., Li, Y. J., Taylor, T. N., Ciliax, B. J., Zachrisson, O., Mercer, A., and Miller, G. W. (2008) PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity Neuropeptides 42, 423-434
25. Partilla, J. S., Dempsey, A. G., Nagpal, A. S., Blough, B. E., Baumann, M. H., and Rothman, R. B. (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter J. Pharmacol. Exp. Ther. 319, 237-246
26. Schwartz, J. W., Blakely, R. D., and DeFelice, L. J. (2003) Binding and transport in norepinephrine transporters J. Biol. Chem. 278, 9768-9777
27. Blakely, R. D., Mason, J. N., Tomlinson, I. D., and Rosenthal, S. J. (2011) Fluorescent substrates for neurotransmitter transporters, U.S. Patent 7947255.
28. Solis, E., Zdravkovic, I., Tomlinson, I. D., Noskov, S. Y., Rosenthal, S. J., and De Felice, L. J. (2012) 4-(4-(Dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter J. Biol. Chem. 287, 8852-8863
29. Fowler, A., Seifert, N., Acker, V., Woehrle, T., Kilpert, C., and de Saizieu, A. (2006) A nonradioactive high-throughput/high-content assay for measurement of the human serotonin reuptake transporter function in vitro J. Biomol. Screen. 11, 1027-1034
30. Wagstaff, R., Hedrick, M., Fan, J., Crowe, P. D., and DiSepio, D. (2007) High-throughput screening for norepinephrine transporter inhibitors using the FLIPRTetra J. Biomol. Screen. 12, 436-441
31. Jørgensen, S., Nielsen, E. Ø., Peters, D., and Dyhring, T. (2008) Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity J. Neurosci. Methods 169, 168-176
32. Bernstein, A. I., Stout, K. A., and Miller, G. W. (2012) A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport J. Neurosci. Methods 209, 357-366
33. Gubernator, N. G., Zhang, H., Staal, R. G. W., Mosharov, E. V., Pereira, D. B., Yue, M., Balsanek, V., Vadola, P. A., Mukherjee, B., Edwards, R. H., Sulzer, D., and Sames, D. (2009) Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals Science 324, 1441-1444
34. Lee, M., Gubernator, N. G., Sulzer, D., and Sames, D. (2010) Development of pH-responsive fluorescent false neurotransmitters J. Am. Chem. Soc. 132, 8828-8830
35. Rodriguez, P. C., Pereira, D. B., Borgkvist, A., Wong, M. Y., Barnard, C., Sonders, M. S., Zhang, H., Sames, D., and Sulzer, D. (2013) Fluorescent dopamine tracer resolves individual dopaminergic synapses and their activity in the brain Proc. Natl. Acad. Sci. U.S.A. 110, 870-875
36. Yelin, R. and Schuldiner, S. (1995) The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters FEBS Lett. 377, 201-207
37. Gasnier, B., Roisin, M. P., Scherman, D., Coornaert, S., Desplanches, G., and Henry, J. P. (1986) Uptake of meta-Iodobenzylguanidine Granule Membranes by Bovine Chromaffin Granule Membranes Mol. Pharmacol. 29, 275-280
38. Reith, M. E. A. (2002) Neurotransmitter Transporters: Structure, Function, and Regulation, 2 nd ed., Humana Press, Totowa, NJ.
39. Pastine, S. J., Youn, S. W., and Sames, D. (2003) Pt(IV)-catalyzed cyclization of arene-alkyne substrates via intramolecular electrophilic hydroarylation Org. Lett. 5, 1055-1058
40. Pastine, S. J., Youn, S. W., and Sames, D. (2003) Pt(IV)-catalyzed cyclization of arene-alkyne substrates via C-H bond functionalization Tetrahedron 59, 8859-8868
41. Vadola, P. A. and Sames, D. (2012) Catalytic coupling of arene C-H bonds and alkynes for the synthesis of coumarins: substrate scope and application to the development of neuroimaging agents J. Org. Chem. 77, 7804-7814
42. Adam, Y., Edwards, R. H., and Schuldiner, S. (2008) Expression and function of the rat vesicular monoamine transporter 2 Am. J. Physiol.: Cell Physiol. 294, C1004-C1011
43. Sabban, E. L., Schwartz, J., and McMahon, A. (1990) Effect of compounds which disrupt proton gradients on secretion of neurosecretory proteins from pc12 pheochromocytoma cells Neuroscience 38, 561-570
44. Yasumoto, S., Tamura, K., Karasawa, J., Hasegawa, R., Ikeda, K., Yamamoto, T., and Yamamoto, H. (2009) Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2 Neurosci. Lett. 454, 229-232
45. Leysen, J. E., Niemegeers, C. J., Van Nueten, J. M., and Laduron, P. M. (1982) [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites Mol. Pharmacol. 21, 301-314
46. Darchen, F., Scherman, D., Laduron, P. M., and Henry, J.-P. (1998) Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles Mol. Pharmacol. 33, 672-677
47. Zhang, J.-H., Chung, T. D. Y., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4, 67-73